Monday, January 28, 2019
Forget Humira -- Here's What You Need to Know About AbbVie
Yesthe times they are a-changin' for Humira. The drug now faces stiff biosimilar competition in Europe. AndyesAbbVie's (NYSE:ABBV) overall performance still hinges largely on Humira.Yes, the times they are a-changin' for Humira. The drug now faces stiff biosimilar competition in Europe. And, yes, AbbVie's (NYSE:ABBV) overall performance still hinges largely on Humira. Read More : https://www.google.com/url?rct=j&sa=t&url=https://www.fool.com/investing/2019/01/27/forget-humira-heres-what-you-need-to-know-about-ab.aspx&ct=ga&cd=CAIyHGM3NmY0MWM4MDgyNGRlMDA6Y29tOmVuOlVTOlI&usg=AFQjCNFTCUcaxEnYuz1V52I1-Rla8cKzqA
Subscribe to:
Post Comments (Atom)
Featured Post
That postcard in the mail about money from a Premera Blue Cross breach settlement is real
If you got a postcard in the mail saying you have money coming from Premera Blue Cross, don't throw it away. It's not junk mail and...
Popular Posts
-
This week, New York City's flourishing CBD market hit a colossal roadblock. On Tuesday, the city's Department of Health put out a di... -
via Google Alert - business http://ift.tt/2q6r9rh
-
Internet descriptions of this technology are not necessarily organized or particularly clear. So, take a look at these 5 blockchain and cry...
-
http://ift.tt/2xIKj63 via /r/business http://ift.tt/2xJbygH
-
If you got a postcard in the mail saying you have money coming from Premera Blue Cross, don't throw it away. It's not junk mail and...
No comments:
Post a Comment